N. Ogata et al., Phosphorothioate oligonucleotides induction into experimental choroidal neovascularization by HVJ-liposome system, CURR EYE R, 18(4), 1999, pp. 261-269
Purpose. The purpose of this study was to determine whether the inactivated
hemagglutinating virus of Japan (HVJ)liposome method can induce phosphorot
hioate oligonucleotides effectively into an experimentally-induced choroida
l neovascularization of rats. We also examined whether antisense phosphorot
hioate oligonucleotides against VEGF could be induced into choroidal neovas
cularization as a therapeutic agent by the HVJ-liposome method.
Methods. The experiments were conducted on a rat model of choroidal neovasc
ularization. FITC-labeled phosphorothioate oligonucleotides were coencapsul
ated in liposomes. The liposomes were coated with the envelope of inactivat
ed HVJ and injected into the vitreous cavity following photocoagulation of-
pigmented rat eyes. The eyes were removed following injection, fixed, froze
n and cut into thin sections. Induction of oligonucleotides was observed un
der a laser confocal scanning microscope for fluorescence and the developme
nt of choroidal neovascularization was evaluated histopathologically.
Results. Phosphorothioate oligonucleotides were effectively induced into ga
nglion cells and into the cells of the choroidal neovascularization induced
by laser photocoagulation. Highly effective induction of oligos was observ
ed 3 to 14 days after intravitreal injection of HVJ-liposomes after which t
he level decreased. Antisense oligonucleotides against VEGF were induced sp
ecifically into cells in the choroidal neovascularization, however neovascu
larization was still observed.
Conclusions. Phosphorothioate oligonucleotides can be effectively induced i
nto ganglion cells, and specifically into cells in choroidal neovasculariza
tion. Although antisense oligonucleotides against VEGF failed to prevent ch
oroidal neovascularization, the HVJ-liposome method provided a highly effec
tive means of inducing antisense oligos for in vivo antisense therapy.